In view of this, our study provided comprehensive data on treatment-related adverse events in BRAF and MEK inhibitor combination therapies, displaying the toxicity profiles of BRAF inhibitors, MEK inhibitors, and combination therapies, providing a valuable tool to guide clinicians in the choice of the optimal therapeutic option for patients with BRAF-mutant melanoma. This evidence concerns the gene BRAF and melanoma.